How Insulin Resistance Affects the Brain

Most conversations about insulin resistance start with blood sugar.

That makes sense, but it is not the whole story.

Insulin resistance often develops alongside increasing visceral fat, higher triglycerides, hypertension, fatty liver disease, poor sleep and declining metabolic flexibility. Those changes affect blood vessels and inflammation throughout the body, including the circulation that supports the brain.

There is also growing interest in insulin signaling inside the brain itself. That research is important, but it is frequently oversimplified online.

We know enough to take metabolic health seriously for cognitive longevity. We do not know enough to blame every episode of brain fog on “brain insulin resistance” or to call Alzheimer's disease simply another form of diabetes.

What Is Insulin Resistance?

Insulin is a hormone produced by the pancreas. Among its many roles, it helps regulate glucose by signaling tissues to take up, store or appropriately use available energy.

With insulin resistance, that signal becomes less effective.

The pancreas can compensate by releasing more insulin. This is one reason someone may have metabolic dysfunction even while fasting glucose and A1C remain within conventional ranges.

Over time, compensation may become inadequate. Glucose rises, first into the prediabetes range and eventually, in some people, into type 2 diabetes.

Insulin resistance is also closely connected with abdominal and visceral adiposity, elevated triglycerides, metabolic dysfunction-associated steatotic liver disease, hypertension and cardiovascular risk.

It is better viewed as part of a metabolic pattern than as an isolated glucose abnormality.

Does the Brain Use Insulin?

Yes, although the role of insulin in the brain differs from its familiar role in muscle and other peripheral tissues.

Insulin receptors are present throughout the central nervous system. Insulin signaling appears to participate in neuronal function, synaptic activity, energy regulation and processes involved in learning and memory.

Researchers have identified abnormalities in insulin signaling in aging brains and in several neurodegenerative conditions. This has generated considerable interest in a concept known as brain insulin resistance.

There is an important distinction here.

Brain insulin resistance is primarily a research concept. We do not currently diagnose it during an office visit with a fasting insulin level, glucose monitor or commercially marketed “brain metabolism” test.

Is Alzheimer's Disease Really “Type 3 Diabetes”?

You may have heard Alzheimer's disease described as “type 3 diabetes.” It is an appealing phrase because it makes a complicated disease sound understandable.

It is also too simplistic.

Insulin signaling abnormalities have been observed in Alzheimer's disease, and diabetes is an established risk factor for dementia. Researchers continue to investigate whether impaired brain insulin signaling contributes directly to Alzheimer's pathology.

But Alzheimer's disease is not clinically classified as diabetes, and the research does not support reducing Alzheimer's disease to one metabolic pathway.

A recent systematic review examining brain insulin resistance and Alzheimer's disease found evidence supporting a relationship in some studies and conflicting findings in others. The authors concluded that the association remains inconclusive.

That is a very different statement from saying that metabolism does not matter. It means we should describe what we know accurately.

The Stronger Evidence: Diabetes and Cognitive Risk

The association between established type 2 diabetes and dementia is considerably more consistent.

A large 2024 meta-analysis involving more than 10 million participants found diabetes was associated with a higher risk of dementia. More recent analyses also suggest that hypoglycemia and other features of longstanding diabetes may further influence cognitive risk.

Diabetes rarely arrives alone, however.

A person with type 2 diabetes may also have hypertension, dyslipidemia, vascular disease, kidney disease, visceral obesity, sleep apnea and physical inactivity. Each can affect brain health independently or in combination.

That is why it is difficult to separate the brain effects of insulin resistance from the larger cardiometabolic environment in which it occurs.

What About Brain Fog?

Brain fog is real as an experience. It is not a diagnosis.

People often use the term to describe difficulty concentrating, mental fatigue, word-finding problems or a sense that thinking is slower than usual.

Metabolic dysfunction may contribute in some people, particularly when it occurs alongside large glucose swings, poor sleep, sleep apnea, obesity or other health problems.

But brain fog has many possible causes. These include:

• Sleep deprivation
• Obstructive sleep apnea
• Menopause and hormone changes
• Thyroid disorders
• Anemia and nutrient deficiencies
• Medication effects
• Depression and anxiety
• Alcohol
• Chronic illness
• Neurologic disease

Calling all of this “insulin resistance in the brain” may sound satisfying, but it can cause us to miss the actual problem.

Visceral Fat Matters More Than the Scale Alone

Two people can weigh the same amount and have very different metabolic health.

Visceral fat surrounds the abdominal organs and is more closely associated with insulin resistance and cardiometabolic risk than body weight alone.

This is one reason we care about body composition rather than relying entirely on BMI or the bathroom scale.

When excess visceral fat decreases, insulin sensitivity and other cardiovascular risk factors often improve. The goal should not be indiscriminate weight loss, particularly as we get older. Losing substantial muscle along with fat creates another problem.

For that reason, body composition becomes especially relevant during weight loss and GLP-1 therapy.

Read more in DEXA, Muscle Mass, and Brain Longevity.

Muscle Is a Metabolic Organ

Skeletal muscle is one of the body's major sites for glucose disposal.

When muscles contract during activity, glucose uptake increases through mechanisms that are not entirely dependent on insulin. Regular exercise also improves insulin sensitivity.

This gives resistance training an important place in metabolic prevention.

Preserving muscle becomes even more important with age because muscle mass and strength naturally tend to decline unless we actively work to maintain them.

We therefore do not think about exercise only as a way to burn calories. Muscle itself is part of glucose regulation, mobility, physical resilience and long-term health.

Sleep Belongs in the Metabolic Conversation

Poor sleep can make metabolic health harder to manage. Obstructive sleep apnea deserves particular attention because it frequently overlaps with visceral obesity, insulin resistance and hypertension.

Someone may focus intensely on glucose while continuing to experience repeated airway obstruction every night.

Those breathing interruptions can produce sympathetic activation, intermittent reductions in oxygen and disrupted sleep, while also making blood-pressure control more difficult.

That combination matters to both cardiovascular and cognitive health.

Read Sleep Apnea and Brain Health.

Blood Pressure May Matter as Much as Glucose

If the goal is preserving cognition, it would be a mistake to focus on insulin while ignoring hypertension.

High blood pressure damages both large and small blood vessels and is an established modifiable risk factor for stroke and cognitive decline.

Insulin resistance and hypertension commonly travel together. Treating one while ignoring the other does not make much sense.

Our longevity approach therefore looks at blood pressure and metabolic health together rather than treating them as separate silos.

Read Hypertension and Longevity: Why Blood Pressure Is About Much More Than Your Heart.

How Do We Know Someone Has Metabolic Dysfunction?

There is no single universally accepted clinical test that tells us a person is “insulin resistant.”

Standard evaluation may include fasting glucose, hemoglobin A1C and, in selected situations, an oral glucose tolerance test. Blood pressure, triglycerides, HDL cholesterol, waist or visceral adiposity, liver health and family history provide additional context.

Fasting insulin can also provide information in clinical practice, but it deserves some caution. Insulin assays are not well standardized between laboratories, and major diabetes laboratory guidelines do not recommend routine insulin testing as a diagnostic test for diabetes or cardiovascular risk.

We may still look at insulin in context when it answers a useful clinical question. We simply do not pretend that one fasting insulin or HOMA-IR cutoff represents a universally accepted diagnosis.

What Can Actually Improve Insulin Sensitivity?

The useful interventions are familiar because they work.

Move More

Regular physical activity improves insulin sensitivity even when dramatic weight loss does not occur. Current diabetes-prevention guidance continues to use approximately 150 minutes of moderate-intensity activity per week as an evidence-based target.

Lift Something

Resistance training helps maintain and build skeletal muscle, giving the body more metabolically active tissue while supporting strength and function with age.

Improve Food Quality

There is no single required macronutrient ratio for preventing diabetes. Mediterranean-style, lower-carbohydrate and other evidence-based patterns can work when they improve overall diet quality and fit the individual.

For most people, a useful place to start is more minimally processed food, adequate protein, vegetables, legumes, nuts, seeds and other fiber-rich foods, while reducing excess refined and ultra-processed foods.

Reduce Excess Visceral Fat

When excess adiposity is present, even modest weight loss can improve glucose regulation and cardiovascular risk factors. The composition of that weight loss matters, which is why preserving muscle remains part of the plan.

Protect Sleep

Sleep duration, sleep quality and sleep apnea deserve attention rather than being treated as optional wellness concerns.

Manage the Rest of the Cardiometabolic Picture

Blood pressure, ApoB-containing lipoproteins, smoking, physical inactivity and other cardiovascular risks continue to matter even if glucose improves beautifully.

What About GLP-1 Medications?

GLP-1 receptor agonists can substantially improve weight and glycemic control in appropriately selected patients, and current observational studies have raised interesting questions about possible effects on dementia risk.

That research should not be translated into a claim that GLP-1 medications prevent Alzheimer's disease. Randomized evidence has not established that conclusion.

What we can say is much simpler: when these medications help someone reduce excess adiposity, improve diabetes or lower cardiometabolic risk, those are meaningful health outcomes in their own right.

The goal should remain comprehensive metabolic care rather than prescribing a medication as a stand-alone “brain longevity” treatment.

A 90-Day Metabolic Reset Is Not Magic

Three months is enough time to see meaningful changes in many metabolic measures.

A1C itself reflects roughly the previous two to three months. Blood pressure, triglycerides, glucose patterns, waist circumference, strength and body composition may also begin to move during this period.

That makes 90 days a useful interval for reassessment.

It does not mean metabolic disease disappears in 90 days.

More useful questions are: Has visceral fat decreased? Has muscle been preserved? Has activity increased? Is sleep better? Is blood pressure controlled? Are glucose and triglycerides moving in the right direction? Can the patient maintain what they are doing?

Those changes tell us much more than whether someone completed a temporary program.

The Longevity Perspective

The metabolic-brain connection is important precisely because so much of it is modifiable.

We cannot look at a brain scan and simply erase every risk for dementia. We can identify hypertension. We can measure metabolic health. We can address excess visceral fat. We can build muscle. We can treat sleep apnea. We can prevent or delay type 2 diabetes in many people.

None guarantees that someone will avoid cognitive decline.

They are still worth doing.

At HormoneSynergy®, brain health is therefore not separated from cardiovascular health, body composition, sleep and metabolism. These systems have been connected all along. Good longevity medicine should be willing to treat them that way.

Selected References

1. American Diabetes Association Professional Practice Committee. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1).
2. American Diabetes Association Professional Practice Committee. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1).
3. American Association for Clinical Chemistry and American Diabetes Association. Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. Diabetes Care. 2023;46:e151-e199.
4. Akhtar A, et al. Brain insulin resistance and Alzheimer's disease: a systematic review. 2024. PMID: 38425702.
5. Cao F, et al. The relationship between diabetes and the dementia risk: a meta-analysis. Diabetology & Metabolic Syndrome. 2024;16:101.
6. Tabesh M, et al. Associations of glycaemia-related risk factors with dementia and cognitive decline in individuals with type 2 diabetes: A systematic review and meta-analysis. Diabetic Medicine. 2025;42:e70123.

This article is for educational purposes and is not intended to diagnose insulin resistance, diabetes, cognitive impairment or another medical condition. Individual evaluation and treatment should be discussed with an appropriate healthcare professional.